Results showing corneal endothelial cell regeneration with sovesudil (starting phase III clinical trial for glaucoma; also known as PHP-201) and PHP-961 was presented at the Association for Research in Vision and Ophthalmology Annual Meeting May 1st – 5th, 2022 (ARVO 2022). This study was conducted at Hallym University in collaboration...
Sovesudil phase II study published in Acta Ophthalmologica
Results testing sovesudil (PHP-201) in normal-tension glaucoma patients in a clinical study was published in the journal Acta Ophthalmologica. This study was funded by pH Pharma and was conducted at 15 clinical centres in South Korea. The study demonstrated the potential of sovesudil in providing intraocular pressure (IOP) reduction in...
Sovesudil neuroprotection results presented at WGC Annual Meeting
Results showing neuroprotection with sovesudil (PHP-201) was presented at the World Glaucoma Congress Annual Meeting June 30th - July 3rd, 2021 (WGC 2021). This study was conducted at The University of Melbourne as a collaboration with pH Pharma. The study demonstrated the potential of sovesudil in providing neuroprotection to neurons...
pH Pharma presents ADC proof-of-concept study results at AACR Annual Meeting
pH Pharma announced proof-of-concept (POC) study results on an antibody-drug conjugate (ADC) containing PH1, pH Pharma's novel toxin payload, at the Association for Cancer Research Annual Meeting April 10-14th, 2021 (AACR 2021). The study demonstrated the potential of PH1 as a potent anti-cancer warhead with immune-stimulatory effects. Highlights: Promising platform...
BenoHoldings “Signed the R&D Agreement for Age-related Macular degeneration with pH Pharma”
BenoBio, a subsidiary of BenoHoldings, has signed a joint R&D Agreement with pH-Pharma.(For more information, please refer to the link below)http://www.newspim.com/news/view/20210217000982
PH Pharma, re-challenge for listing… 8 Billion KRW funding at the end of last year
PH Pharma, which could not exceed the threshold of the KOSDAQ preliminary examination last year, plans to re-challenge this year's IPO.(For more information, please refer to the link below)http://www.thebell.co.kr/free/Content/ArticleView.asp?key=202101081242287200105995
pH Pharma Develops New Drugs through Synergy between US and Korea
Sanjeev Satyal, Head of R&D of pH PhamaImplement new technology and culture from U.S.Basic research for new drug candidate in KoreaDeveloping glaucoma and NASH treatments(For more information, please refer to the link below)https://www.hankyung.com/it/article/202003033648i
pH Pharma IND approval for “Alpha-1 Antitrypsin Deficiency treatment” Phase 2 clinical trial in Europe
PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.(For more information, please refer to the link below)https://www.edaily.co.kr/news/read?newsId=02745366625637392
The reason why the US FDA was able to quickly approve the new ADC drug, Enhertu
New ADC deals between big pharma made recentlypH Pharma builds toxin library for ADC development(For more information, please refer to the link below)http://www.medigatenews.com/news/1001974809
pH Pharma passed technical evaluation
Received “Pass” from two tech evaluation agencies… Target to file preliminary review application to KOSDAQExpanding global new drug development platform through IPO. Accelerating innovation for new drug development and business development(For more information, please refer to the link below)https://www.hankyung.com/it/article/201912276015i